BioSpace News Archive

Polaris Group, announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis.

Xenon Pharmaceuticals Inc. announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement.

Oxford BioTherapeutics today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BI 764532.

Alpha Tau Medical Ltd. today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7th, 2023.

Dyadic International, Inc. today announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100.

Intelligent Bio Solutions Inc. today announced that it will present at the Emerging Growth Conference on December 7, 2023.

SELLAS Life Sciences Group, Inc. today announced that the target patient enrollment outside of mainland China in the ongoing Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML).

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.

Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced positive results from its first in-human study of QN-01, the company’s lead asset.

ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failure, a series of failed surgical by-pass grafts and severe mitral regurgitation (MR 4+), was successfully treated with the Palmetto System.